Article: Fasting total plasma homocysteine and atherosclerotic peripheral vascular disease

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleFasting total plasma homocysteine and atherosclerotic peripheral vascular disease
AuthorsCheng, SWK1
Ting, ACW1
Wong, J1
Issue Date1997
PublisherElsevier Inc.
CitationAnnals Of Vascular Surgery, 1997, v. 11 n. 3, p. 217-223 [How to Cite?]
DOI: http://dx.doi.org/10.1007/s100169900037
AbstractFasting total plasma homocysteine levels were measured by rapid ion- exchange chromatography in 100 patients with symptomatic atherosclerotic peripheral vascular disease (PVD) and 100 age and sex-matched control subjects. Demographic data, biochemistry, hematology, and lipid fractions were measured in both groups, and clinical and vascular laboratory disease parameters were recorded for the patient group. Patients with hyperhomocysteinemia (defined as those with fasting homocysteine values exceeding the 90th percentile of the control range) were compared to patients with normal homocysteine with respect to the above parameters. Total fasting homocysteine concentrations were significantly higher in the patient group (28.8 ± 14.9 μmol/l) than in the control subjects (20.3 ± 11.3 μmol/l; p < 0.001). Homocysteine levels were also higher in males than in females in both the control and the patient groups. Homocysteine correlates positively only with age in the healthy controls (r = 0.291; p < 0.005) but not with other standard risk factors. Multivariate analysis of the biochemical risk factors confirmed that total plasma homocysteine concentration is an independent risk factor for PVD (p < 0.001). Hyperhomocysteinemia is not associated with vitamin B12 or folate deficiency states. Vitamin B12 concentration was 591 ± 313 ng/l in the control group, and 682 ± 405 ng/l in the patient group (p = NS). Serum relate concentration was lower in the controls (7.2 ± 2.3 μg/l) than in the patients (8.3 ± 2.0 μg/I, p < 0.001). Mild hyperhomocysteinemia was detected in 27% of the patients. Patients with hyperhomocysteinemia has a four-fold increase in risk of PVD relative to patients with a normal homocysteine level. There is no significant difference between the two groups with respect to patient demographics, biochemical risk factors, and disease pattern and severity.
ISSN0890-5096
2011 Impact Factor: 1.035
2011 SCImago Journal Rankings: 0.092
DOIhttp://dx.doi.org/10.1007/s100169900037
ISI Accession Number IDWOS:A1997WW54300001
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorCheng, SWK
dc.contributor.authorTing, ACW
dc.contributor.authorWong, J
dc.date.accessioned2010-09-06T08:47:13Z
dc.date.available2010-09-06T08:47:13Z
dc.date.issued1997
dc.description.abstractFasting total plasma homocysteine levels were measured by rapid ion- exchange chromatography in 100 patients with symptomatic atherosclerotic peripheral vascular disease (PVD) and 100 age and sex-matched control subjects. Demographic data, biochemistry, hematology, and lipid fractions were measured in both groups, and clinical and vascular laboratory disease parameters were recorded for the patient group. Patients with hyperhomocysteinemia (defined as those with fasting homocysteine values exceeding the 90th percentile of the control range) were compared to patients with normal homocysteine with respect to the above parameters. Total fasting homocysteine concentrations were significantly higher in the patient group (28.8 ± 14.9 μmol/l) than in the control subjects (20.3 ± 11.3 μmol/l; p < 0.001). Homocysteine levels were also higher in males than in females in both the control and the patient groups. Homocysteine correlates positively only with age in the healthy controls (r = 0.291; p < 0.005) but not with other standard risk factors. Multivariate analysis of the biochemical risk factors confirmed that total plasma homocysteine concentration is an independent risk factor for PVD (p < 0.001). Hyperhomocysteinemia is not associated with vitamin B12 or folate deficiency states. Vitamin B12 concentration was 591 ± 313 ng/l in the control group, and 682 ± 405 ng/l in the patient group (p = NS). Serum relate concentration was lower in the controls (7.2 ± 2.3 μg/l) than in the patients (8.3 ± 2.0 μg/I, p < 0.001). Mild hyperhomocysteinemia was detected in 27% of the patients. Patients with hyperhomocysteinemia has a four-fold increase in risk of PVD relative to patients with a normal homocysteine level. There is no significant difference between the two groups with respect to patient demographics, biochemical risk factors, and disease pattern and severity.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationAnnals Of Vascular Surgery, 1997, v. 11 n. 3, p. 217-223 [How to Cite?]
DOI: http://dx.doi.org/10.1007/s100169900037
dc.identifier.doihttp://dx.doi.org/10.1007/s100169900037
dc.identifier.epage223
dc.identifier.hkuros32365
dc.identifier.isiWOS:A1997WW54300001
dc.identifier.issn0890-5096
2011 Impact Factor: 1.035
2011 SCImago Journal Rankings: 0.092
dc.identifier.issue3
dc.identifier.openurl
dc.identifier.pmid9140594
dc.identifier.scopuseid_2-s2.0-0030897348
dc.identifier.spage217
dc.identifier.urihttp://hdl.handle.net/10722/83957
dc.identifier.volume11
dc.languageeng
dc.publisherElsevier Inc.
dc.publisher.placeUnited States
dc.relation.ispartofAnnals of Vascular Surgery
dc.relation.referencesReferences in Scopus
dc.rightsAnnals of Vascular Surgery. Copyright © Elsevier Inc.
dc.titleFasting total plasma homocysteine and atherosclerotic peripheral vascular disease
dc.typeArticle
Author Affiliations
  1. The University of Hong Kong